TickerFacts.

Dexcom Inc (DXCM): R&D Expense

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2011-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$599.10M
Year ended 2025-12-31
$604.00M
Trailing 12 months to 2026-06-30
+7.4%
3-year compound annual growth
+10.7%
5-year compound annual growth
+15.9%
10-year compound annual growth
2009-12-31: $14.29M2010-12-31: $23.20M2011-12-31: $29.60M2012-12-31: $38.30M2013-12-31: $44.80M2014-12-31: $69.40M2015-12-31: $137.50M2016-12-31: $156.10M2017-12-31: $185.40M2018-12-31: $199.70M2019-12-31: $273.50M2020-12-31: $359.90M2021-12-31: $517.10M2022-12-31: $484.20M2023-12-31: $505.80M2024-12-31: $552.40M2025-12-31: $599.10M$599.10M
2009-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$599.10M+8.5%2026-02-12, From 2025-01-01
2024-12-31$552.40M+9.2%2026-02-12, From 2024-01-01
2023-12-31$505.80M+4.5%2026-02-12, From 2023-01-01
2022-12-31$484.20M-6.4%2025-02-18, From 2022-01-01
2021-12-31$517.10M+43.7%2024-02-08, From 2021-01-01
2020-12-31$359.90M+31.6%2023-02-09, From 2020-01-01
2019-12-31$273.50M+37.0%2022-02-14, From 2019-01-01
2018-12-31$199.70M+7.7%2021-02-11, From 2018-01-01
2017-12-31$185.40M+18.8%2020-02-13, From 2017-01-01
2016-12-31$156.10M+13.5%2019-02-21, From 2016-01-01
2015-12-31$137.50M+98.1%2018-02-27, From 2015-01-01
2014-12-31$69.40M+54.9%2017-02-28, From 2014-01-01
2013-12-31$44.80M+17.0%2016-02-23, From 2013-01-01
2012-12-31$38.30M+29.4%2015-02-25, From 2012-01-01
2011-12-31$29.60Mn/c2014-02-20, From 2011-01-01
2010-12-31$23.20M+62.3%2013-02-21, From 2010-01-01
2009-12-31$14.29Mn/a2012-02-23, From 2009-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Surgical & Medical Instruments & Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Dexcom Inc (DXCM)2025-12-31$599.10M+8.5%
ResMed Inc (RMD)2026-06-30$378.29M+14.2%
MiniMed Group, Inc. (MMED)2026-04-24$448.00M+2.8%
West Pharmaceutical Services Inc (WST)2025-12-31$74.30M+7.5%
Globus Medical Inc (GMED)2025-12-31$147.25M-10.1%
Insulet Corp (PODD)2025-12-31$301.10M+37.1%
Solventum Corp (SOLV)2025-12-31$739.00M-4.6%
ICU Medical Inc (ICUI)2025-12-31$87.50M-1.3%
Teleflex Inc (TFX)2025-12-31$144.78M+32.8%

Compare DXCM, RMD, MMED, WST side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗